ANALYZING THE IMPACT OF STATINS USE IN TYPE 2 DIABETES MELLITUS PATIENTS AT A TERTIARY CARE HOSPITAL IN ANDHRA PRADESH

Authors

  • PANCHUMARTHI DIVYA JYOTHI Department of Pharmacy Practice, Nirmala College of Pharmacy, Guntur, Andhra Pradesh, India.
  • PONNADA SRI DURGA Department of , Nirmala College of Pharmacy, Guntur, Andhra Pradesh, India.
  • YERUVA VEENA Department of , Nirmala College of Pharmacy, Guntur, Andhra Pradesh, India.
  • SHAIK AFSARI Department of , Nirmala College of Pharmacy, Guntur, Andhra Pradesh, India.

DOI:

https://doi.org/10.22159/ajpcr.2020.v13i8.37862

Keywords:

Type 2 diabetes mellitus, New-onset diabetic statins, Fasting blood sugar, Post-prandial blood sugar, Glycated hemoglobin, Cardiovascular disease

Abstract

Objectives: The objectives of the study were to analyze the impact of statins uses in Type-2 diabetes mellitus patients at a tertiary hospital.

Methods: It is a hospital-based prospective and observational study. The study was conducted in the General Medicine Department of Manipal Super Speciality Hospital, Vijayawada, Andhra Pradesh, India. Six months (August 2018–January 2019), 450 cases were collected from the general medicine department.

Results: A total of 450 patients data were collected, the results show that rosuvastatin at its list dose in this study (10 mg) was more effective at reducing fasting blood sugar (FBS), post-prandial blood sugar (PPBS), and hemoglobin A1C (HbA1c) levels than rosuvastatin combination. Moreover, significant increment of these levels (FBS, PPBS, and HbA1c) was observed with atorvastatin combination followed by atorvastatin (10 mg, 20 mg, and 40 mg) in both treatment group as well as a control group.

Conclusion: We concluded that there is a significant rise in blood glucose levels (both FBS and PPBS) and also HbA1c levels (glycated hemoglobin) due to the usage of statins for a longer duration. Statistical analysis was performed using the Pearson correlation coefficient method (SPSS 20. Version) and two-tailed analysis of variance. The results were represented as Z value (correlation coefficient) and p-value.

Downloads

Download data is not yet available.

References

Shargel L, Mutnick AH, Swanson LN. Comprehensive Pharmacy Review. 8th ed. United States: Lippincott, Williams and Wilkins Publishers; 2013.

Tripathi KD. Essentials of Medical Pharmacology. 7th ed. Tamil Nadu: Jaypee Publishers; 2013.

Dipiro JT, Talbert R, Yee G, Matzke G, Wells B, Posey LM. Pharmacotherapy-a Pathophysiologic Approach. 10th ed. United States: McGraw-Hill Education Publishers; 2017.

Krauss RM. Lipids and lipoproteins in patients with Type 2 diabetes. Diabetes Care 2004;27:1496-504.

Vani C, Narayana BL, Prashanthi P, Karthik B. Analyzing the impact of statins use in Type-2 diabetes mellitus patients. IOSR J Pharm Biol Sci 2018;13:45-53.

Baum T, Yap SP, Karampinos DC, Nardo L, Kuo D, Burghardt AJ, et al. Does vertebral bone marrow fat content correlate with abdominal adipose tissue, lumbar spine bone mineral density, and blood biomarkers in women with Type 2 diabetes mellitus? J Magn Reson Imaging 2012;35:117-24.

Miettinen TA. Diurnal variation of cholesterol precursors squalene and methyl sterols in human plasma lipoproteins. J Lipid Res 1982;23:466-73.

Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376:1670-81.

Saito Y, Yoshida S, Nakaya N, Hata Y, Goto Y. Comparison between morning and evening doses of simvastatin in hyperlipidemic subjects. A double-blind comparative study. Arterioscler Thromb 1991;11:816-26.

Wallace A, Chinn D, Rubin G. Taking simvastatin in the morning compared within the evening: Randomised controlled trial. BMJ 2003;327:788.

Published

07-08-2020

How to Cite

DIVYA JYOTHI, P., P. SRI DURGA, Y. VEENA, and S. AFSARI. “ANALYZING THE IMPACT OF STATINS USE IN TYPE 2 DIABETES MELLITUS PATIENTS AT A TERTIARY CARE HOSPITAL IN ANDHRA PRADESH”. Asian Journal of Pharmaceutical and Clinical Research, vol. 13, no. 8, Aug. 2020, pp. 131-7, doi:10.22159/ajpcr.2020.v13i8.37862.

Issue

Section

Original Article(s)